نتایج جستجو برای: 4 dihydropyrimidine

تعداد نتایج: 1304168  

Journal: :Oncology 2000
C H Köhne G J Peters

The mechanism of action of fluorouracil (5-FU) and the oral fluoropyrimidines and the importance of biochemical modulation and inhibition of dihydropyrimidine dehydrogenase for oral application of the prodrugs of 5-FU are discussed. The regulation of thymidylate synthase, as well as its roles as a target for antineoplastic activity and in drug resistance, are also mentioned. The more downstream...

Journal: :Cancer research 1986
C Desgranges G Razaka E De Clercq P Herdewijn J Balzarini F Drouillet H Bricaud

In contrast to thymine and 5-fluorouracil (FUra) which were cleared from the bloodstream within 2-4 h after their i.p. administration (200 mumol/kg) to rat, (E)-5-(2-bromovinyl)uracil (BVUra) maintained a concentration of 50-70 microM for at least 6 h and was still present in the plasma 24 h after its administration. In vitro experiments with rat liver extracts indicated that BVUra was not a su...

2004
EKC YAU CC SHEK KY CHAN AYW CHAN

Received April 10, 2003 Abstract Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disorder of pyrimidine catabolism. This enzyme deficiency has a wide phenotypic variability but neurological abnormalities like convulsion, motor developmental delay and mental retardation are common. DPD deficiency is also associated with increased risk of toxicity in patients receiving ...

Journal: :Clinical pharmacology and therapeutics 2011
J J Swen M Nijenhuis A de Boer L Grandia A H Maitland-van der Zee H Mulder G A P J M Rongen R H N van Schaik T Schalekamp D J Touw J van der Weide B Wilffert V H M Deneer H-J Guchelaar

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations w...

Journal: :The oncologist 2000
S Sharma L B Saltz

A number of novel oral chemotherapeutic agents are entering practice or are under development in the United States. Many of these agents display significant clinical activity against colorectal cancer. Many classes of compounds, including fluoropyrimidine analogs, dihydropyrimidine dehydrogenase (DPD) inhibitors, topoisomerase inhibitors, farnesyl transferase inhibitors, and others, are being d...

2015
Dilsa Mizrak Ali Alkan Batuhan Erdogdu Gungor Utkan

Osteogenesis imperfecta (OI) is a rare, inherited skeletal disorder characterized by abnormalities of type 1 collagen. Malignancy is rarely reported in patients with OI and it was suggested that this disease can protect against cancer. Here, we report a 41-year-old woman with symptoms of achalasia where repeated treatment of pneumatic dilation and stent replacement was unsuccessful; therefore, ...

2015
Durga Prasad

Background and Objective: A Simple, Green and efficient procedure for the synthesis of 4-aryl-3, 4-dihydropyrimidine-2(1H)-ones/thione (Biginelli reaction) from 1, 3-dicarbonyl compound, substituted aldehydes and urea/thiourea in the presence of Sodium Dodecyl Sulphate (SDS), a novel catalyst has been introduced in this study. Materials and Methods: The structures of these compounds have been c...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2005
Stephen J Stray Christina R Bourne Sreenivas Punna Warren G Lewis M G Finn Adam Zlotnick

Heteroaryldihydropyrimidines (HAPs) are a new class of antivirals inhibiting production of hepatitis B virus (HBV) virions in tissue culture. Here, we examine the effect of a representative HAP molecule, methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP-1), on the in vitro assembly of HBV capsid protein (Cp). HAP-1 enhances the rate and extent...

2016
Dominic A. Colosimo John B. MacMillan

Discoipyrroles A-D (DPA-DPD) are recently discovered natural products produced by the marine bacterium Bacillus hunanensis that exhibit anticancer properties in vitro. Initial biosynthetic studies demonstrated that DPA is formed in the liquid fermentation medium of B. hunanensis from three secreted metabolites through an unknown but protein-independent mechanism. The increased identification of...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید